Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Improper Staffer Involvement in 4 More Japan CML Programs: Novartis
May 20, 2014
-
REGULATORY PIC/S Committee OKs Japan’s Accession from July 2014
May 20, 2014
-
ACADEMIA Sapporo Hospital Sorry for Ethical Guidelines Violations in Nesp Clinical Study
May 19, 2014
-
BUSINESS Jury Finds in Favor of Takeda in Actos Lawsuit, Turning Down Plaintiff’s Claim
May 19, 2014
-
BUSINESS Generic Makers See Softer Sales Growth in FY2013
May 16, 2014
-
BUSINESS Daiichi Sankyo Chair Shoda to Bow Out, Become Adviser
May 16, 2014
-
REGULATORY Chuikyo OKs NHI Price Listing of SGLT-2 Inhibitors, New Point-Based Calculations Adopted from This Time
May 15, 2014
-
BUSINESS Santen Acquires Merck’s Eye Drugs in Japan, Key Markets
May 14, 2014
-
REGULATORY PIC/S to Discuss Japan’s Accession at Upcoming Meeting in Rome; MHLW Anticipates Formal Approval
May 14, 2014
-
BUSINESS 4 Major Wholesalers’ Average Operating Margin Tops 1% Mark, Signaling Biz Recovery
May 13, 2014
-
BUSINESS Astellas Pres. “Aware” of Rumored Marriage with Daiichi Sankyo, but Denies Any Merger at This Time
May 13, 2014
-
BUSINESS FY2013 Japan Ethical Drug Market Crosses 10 Trillion Yen Mark for 1st Time: IMS
May 12, 2014
-
BUSINESS MTPC to Push Tenelia, Canaglu to Compete in Diabetes Field
May 9, 2014
-
BUSINESS Eisai Moves to Boost Global Use of Products via Emerging Market Businesses
May 8, 2014
-
REGULATORY Pilot Program for Compassionate Access System Gets Underway with Sanofi’s Cabazitaxel
May 7, 2014
-
REGULATORY Joint Panel of Health, Science Ministries Wraps Up Talks on Ethics Code for Epidemiological, Clinical Research
May 2, 2014
-
REGULATORY Point-Based Calculations for Premiums Will Improve Predictability, Says Creator
May 1, 2014
-
BUSINESS Takeda, Teva to Commercialize Teva’s Parkinson’s Disease Treatment Rasagiline in Japan
April 30, 2014
-
ACADEMIA Chiba University to Advise Researchers to Retract Diovan Papers
April 28, 2014
-
REGULATORY MHLW Bureaucrats Think Chuikyo Will Spurn Annual Drug Price Revisions, Again
April 28, 2014
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…